Cite
HARVARD Citation
Hay, A. et al. (n.d.). A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191. Leukemia & lymphoma. 57 (6), pp. 1463-1466. [Online].